Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released Aug 6, 2024, after the close
10-Q filed Aug 7, 2024, 38 days after period end · 0000950170-24-092163
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $241.96M | $165.24M | $134.56M | $115.22M |
| Net Income | $33.39M | $1.11M | -$34.01M | -$43.87M |
| EPS Diluted |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| $0.20 |
| $0.01 |
| -$0.21 |
| -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
